References
- Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2: 471–8
- Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327–37
- O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597–605
- Pfizer Inc., data on file.
- Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future trial development. Nat Rev Drug Discov 2007; 6: 734–45
- Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 143: 313–4
- Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French Sarcoma Group. J Clin Oncol 2007; 25: 1107–13
- Blay, JY, George, S, Casali, PG, Le Cesne, A, Morgan, JA, Tyler, A, , et al. Clinical benefit of continuous daily dosing of sunitinib in patients (pts) with advanced gastrointestinal stromal tumor (GIST). Ann Oncol 2006;17(Suppl 9): 508P (Abstract).
- Escudier, B, Roigas, J, Gillessen, S, Srinivas, S, Pisa, P, Vogelzang, N, , et al. Continuous daily administration of sunitinib malate (SU11248)-phase II study in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (MRCC). Ann Oncol 2006, 17(Suppl 9): 436O (Abstract).
- Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara Yao VJ, et al. Rapid vascular regrowth in tumours after reversal of VEGF inhibition. J Clin Invest 2006; 116: 2610–21